2012 FDA drug approvals

被引：0

|

作者：

Asher Mullard

机构：

来源：

Nature Reviews Drug Discovery | 2013年 / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

FDA drug approval bonanza sees cancer and orphan drugs on top again.

引用

收藏

页码：87 / 90

页数：3

相关论文

共 50 条

[21] 2019 FDA drug approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (02) : 79 - 84
[22] 2020 FDA drug approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (02) : 85 - 90
[23] 2020 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2021, 20 : 85 - 90
[24] 2010 FDA drug approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) : 82 - 85
[25] FDA Guidance and New Drug Approvals
Walker, Scot
[J]. HOSPITAL PHARMACY, 2018, 53 (06) : 360 - 362
[26] Pharmaceuticals - Drug approvals from the FDA
不详
[J]. EUROPEAN CHEMICAL NEWS, 1997, 68 (1783): : 31 - 31
[27] Erratum: 2010 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2011, 10 (3) : 237 - 237
[28] Erratum: 2017 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2018, 17 (2) : 150 - 150
[29] Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey
Yu, Tsung
Hsu, Yea-Jen
Fain, Kevin M.
Boyd, Cynthia M.
Holbrook, Janet T.
Puhan, Milo A.
[J]. BMJ OPEN, 2015, 5 (11):
[30] FDA moves to speed cancer drug approvals
Reynolds, T
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (08) : 491 - 491

← 1 2 3 4 5 →